nach oben

Current Hypertension Reports

Erschienen in:

01.11.2017 | Preeclampsia (VD Garovic, Section Editor)

The Complement System and Preeclampsia

verfasst von: Jean F. Regal, Richard M. Burwick, Sherry D. Fleming

Erschienen in: Current Hypertension Reports | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Preeclampsia affects 3–4% of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed.

Recent Findings

Studies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies.

Summary

Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.

Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7. https://doi.org/10.1016/j.ejogrb.2013.05.005.PubMedCrossRef

ACOG. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31. https://doi.org/10.1097/01.AOG.0000437382.03963.88.CrossRef

Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013;347:f6564. https://doi.org/10.1136/bmj.f6564.PubMedPubMedCentralCrossRef

Alsnes IV, Vatten LJ, Fraser A, Bjorngaard JH, Rich-Edwards J, Romundstad PR, et al. Hypertension in pregnancy and offspring cardiovascular risk in young adulthood: prospective and sibling studies in the HUNT study (Nord-Trondelag Health Study) in Norway. Hypertension. 2017;69(4):591–8. https://doi.org/10.1161/HYPERTENSIONAHA.116.08414.PubMedCrossRef

Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078. https://doi.org/10.1136/bmj.j3078.PubMedPubMedCentralCrossRef

Best LG, Lunday L, Webster E, Falcon GR, Beal JR. Pre-eclampsia and risk of subsequent hypertension: in an American Indian population. Hypertens Pregnancy Off J Int Soc Study Hypertens Pregnancy. 2017;36(2):131–7. https://doi.org/10.1080/10641955.2016.1250905.CrossRef

Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol. 1982;142(2):159–67.PubMedCrossRef

Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, et al. Screening for preeclampsia: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(16):1661–7. https://doi.org/10.1001/jama.2017.3439.CrossRef

Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–4. https://doi.org/10.1126/science.1111726.PubMedCrossRef

10.

Blois SM, Dechend R, Barrientos G, Staff AC. A potential pathophysiological role for galectins and the renin-angiotensin system in preeclampsia. Cell Mol Life Sci. 2015;72(1):39–50. https://doi.org/10.1007/s00018-014-1713-1.PubMedCrossRef

11.

Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534–43. https://doi.org/10.1111/j.1600-0897.2010.00831.x.PubMedCrossRef

12.

Pilliod RA, Feinberg BB, Burwick RM. Maternal and feto-placental phenotypes of early-onset severe preeclampsia. J Matern Fetal Neonatal Medicine. 2016;29(8):1209–13. https://doi.org/10.3109/14767058.2015.1045867.CrossRef

13.

•• Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39(6):1143–57. https://doi.org/10.1016/j.immuni.2013.10.018. First description of the intracellular pathway for generation of C3a and C5a. PubMedPubMedCentralCrossRef

14.

Samstad EO, Niyonzima N, Nymo S, Aune MH, Ryan L, Bakke SS, et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol. 2014;192(6):2837.PubMedPubMedCentralCrossRef

15.

Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cells. Science. 2016;352(6292)

16.

Arbore G, Kemper C. A novel "complement-metabolism-inflammasome axis" as a key regulator of immune cell effector function. Eur J Immunol. 2016;46(7):1563–73. https://doi.org/10.1002/eji.201546131.PubMedPubMedCentralCrossRef

17.

Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science. 2016;352(6292):aad1210. https://doi.org/10.1126/science.aad1210.PubMedPubMedCentralCrossRef

18.

Haggadone MD, Grailer JJ, Fattahi F, Zetoune FS, Ward PA. Bidirectional crosstalk between C5a receptors and the NLRP3 inflammasome in macrophages and monocytes. Mediat Inflamm. 2016;2016:1340156. https://doi.org/10.1155/2016/1340156.CrossRef

19.

• Satyam A, Kannan L, Matsumoto N, Geha M, Lapchak PH, Bosse R, et al. Intracellular activation of complement 3 is responsible for intestinal tissue damage during mesenteric ischemia. J Immunol. 2017;198(2):788. Demonstrates the intracellular complement pathway in an injury model and suggests that different cathepsins are operative in distinct cell types. PubMedCrossRef

20.

Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35

21.

Zabel MK, Kirsch WM. From development to dysfunction: microglia and the complement cascade in CNS homeostasis. Ageing Res Rev. 2013;12(3):749–56. https://doi.org/10.1016/j.arr.2013.02.001.PubMedPubMedCentralCrossRef

22.

Fonseca MI, Chu SH, Hernandez MX, Fang MJ, Modarresi L, Selvan P, et al. Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflammation. 2017;14(1):48. https://doi.org/10.1186/s12974-017-0814-9.PubMedPubMedCentralCrossRef

23.

Thielens NM, Tedesco F, Bohlson SS, Gaboriaud C, Tenner AJ. C1q: a fresh look upon an old molecule. Mol Immunol. 2017; https://doi.org/10.1016/j.molimm.2017.05.025.

24.

Gorelik A, Sapir T, Haffner-Krausz R, Olender T, Woodruff TM, Reiner O. Developmental activities of the complement pathway in migrating neurons. Nat Commun. 2017;8:15096. https://doi.org/10.1038/ncomms15096.PubMedPubMedCentralCrossRef

25.

Jiang TT, Chaturvedi V, Ertelt JM, Kinder JM, Clark DR, Valent AM, et al. Regulatory T cells: new keys for further unlocking the enigma of fetal tolerance and pregnancy complications. J Immunol. 2014;192(11):4949–56. https://doi.org/10.4049/jimmunol.1400498.PubMedPubMedCentralCrossRef

26.

La Rocca C, Carbone F, Longobardi S, Matarese G. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett. 2014;(1 Pt A):162, 41–8. https://doi.org/10.1016/j.imlet.2014.06.013.

27.

Rahimzadeh M, Norouzian M, Arabpour F, Naderi N. Regulatory T-cells and preeclampsia: an overview of literature. Expert Rev Clin Immunol. 2016;12(2):209–27. https://doi.org/10.1586/1744666X.2016.1105740.PubMedCrossRef

28.

Matias ML, Romao M, Weel IC, Ribeiro VR, Nunes PR, Borges VT, et al. Endogenous and uric acid-induced activation of NLRP3 inflammasome in pregnant women with preeclampsia. PLoS One. 2015;10(6):e0129095. https://doi.org/10.1371/journal.pone.0129095.PubMedPubMedCentralCrossRef

29.

Mulla MJ, Myrtolli K, Potter J, Boeras C, Kavathas PB, Sfakianaki AK, et al. Uric acid induces trophoblast IL-1beta production via the inflammasome: implications for the pathogenesis of preeclampsia. Am J Reprod Immunol. 2011;65(6):542–8. https://doi.org/10.1111/j.1600-0897.2010.00960.x.PubMedPubMedCentralCrossRef

30.

Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) regulatory T cells. Nat Immunol. 2013;14(2):162–71. https://doi.org/10.1038/ni.2499.PubMedCrossRef

31.

Drouin SM, Sinha M, Sfyroera G, Lambris JD, Wetsel RA. A protective role for the fifth complement component (c5) in allergic airway disease. Am J Respir Crit Care Med. 2006;173(8):852–7. https://doi.org/10.1164/rccm.200503-334OC.PubMedPubMedCentralCrossRef

32.

Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med. 1981;153(3):665–76.PubMedCrossRef

33.

Krisinger MJ, Goebeler V, Lu Z, Meixner SC, Myles T, Pryzdial EL, et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood. 2012;120(8):1717–25. https://doi.org/10.1182/blood-2012-02-412080.PubMedCrossRef

34.

Kozarcanin H, Lood C, Munthe-Fog L, Sandholm K, Hamad OA, Bengtsson AA, et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost. 2016;14(3):531–45. https://doi.org/10.1111/jth.13208.PubMedCrossRef

35.

Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794–802.PubMedCrossRef

36.

Erez O, Gotsch F, Mazaki-Tovi S, Vaisbuch E, Kusanovic JP, Kim CJ, et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med. 2009;22(8):672–87. https://doi.org/10.1080/14767050902853117.PubMedCrossRef

37.

Redecha P, van Rooijen N, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood. 2009;113(17):4101–9. https://doi.org/10.1182/blood-2008-12-194258.PubMedPubMedCentralCrossRef

38.

Rayes J, Roumenina LT, Dimitrov JD, Repesse Y, Ing M, Christophe O, et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood. 2014;123(1):121–5. https://doi.org/10.1182/blood-2013-04-495853.PubMedCrossRef

39.

•• Lokki AI, Kaartokallio T, Holmberg V, Onkamo P, Koskinen LLE, Saavalainen P, et al. Analysis of complement C3 gene reveals susceptibility to severe preeclampsia. Front Immunol. 2017;8:589. https://doi.org/10.3389/fimmu.2017.00589. Describes association of SNP haplotype within C3 gene that influences susceptibility to severe forms of preeclampsia. PubMedPubMedCentralCrossRef

40.

• Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8(3):e1001013. https://doi.org/10.1371/journal.pmed.1001013. Demonstration of the importance of complement regulatory proteins in maintaining a successful pregnancy. PubMedPubMedCentralCrossRef

41.

Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2008;111(2):624–32. https://doi.org/10.1182/blood-2007-04-084533.PubMedPubMedCentralCrossRef

42.

Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008;198(4):385 e1-9. https://doi.org/10.1016/j.ajog.2007.10.793.PubMedPubMedCentralCrossRef

43.

Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. 2011;117(1):75–83. https://doi.org/10.1097/AOG.0b013e3181fc3afa.PubMedPubMedCentralCrossRef

44.

Lynch AM, Eckel RH, Murphy JR, Gibbs RS, West NA, Giclas PC, et al. Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol. 2012;(5):206, 428 e1-8. https://doi.org/10.1016/j.ajog.2012.02.035.

45.

Cushen SC, Goulopoulou S. New models of pregnancy-associated hypertension. Am J Hypertens. 2017; https://doi.org/10.1093/ajh/hpx063.

46.

Sones JL, Davisson RL. Preeclampsia, of mice and women. Physiol Genomics. 2016;48(8):565–72. https://doi.org/10.1152/physiolgenomics.00125.2015.PubMedPubMedCentralCrossRef

47.

Davisson RL, Hoffmann DS, Butz GM, Aldape G, Schlager G, Merrill DC, et al. Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension. 2002;39(2 Pt 2):337–42.PubMedCrossRef

48.

Dokras A, Hoffmann DS, Eastvold JS, Kienzle MF, Gruman LM, Kirby PA, et al. Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia. Biol Reprod. 2006;75(6):899–907. https://doi.org/10.1095/biolreprod.106.053603.PubMedCrossRef

49.

• Gelber SE, Brent E, Redecha P, Perino G, Tomlinson S, Davisson RL, et al. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J Immunol. 2015;195(3):1129–38. https://doi.org/10.4049/jimmunol.1402220. An important animal model of preeclampsia demonstrating the importance of excessive complement activation in adversely affecting placental development. PubMedPubMedCentralCrossRef

50.

Sones JL, Merriam AA, Grenier J, Douglas NA, Davisson RL. Inflammatory mediators during the pre-implantation period play a key role in the pathogenesis of preeclampsia in the spontaeous preeclamptic-like BPH/5 mouse. FASEB J Off Publ Fed Am Soc Exp Biol. 2017;31(1):1033.

51.

Sutton EF, Lob HE, Song J, Xia Y, Butler S, Liu CC, et al. Adverse metabolic phenotype of female offspring exposed to preeclampsia in utero: a characterization of the BPH/5 mouse in postnatal life. Am J Physiol Regul Integr Comp Physiol. 2017;312(4):R485–R91. https://doi.org/10.1152/ajpregu.00512.2016.PubMedCrossRef

52.

Agostinis C, Bulla R, Tripodo C, Gismondi A, Stabile H, Bossi F, et al. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol. 2010;185(7):4420–9. https://doi.org/10.4049/jimmunol.0903215.PubMedCrossRef

53.

Bulla R, Agostinis C, Bossi F, Rizzi L, Debeus A, Tripodo C, et al. Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol Immunol. 2008;45(9):2629–40. https://doi.org/10.1016/j.molimm.2007.12.025.PubMedPubMedCentralCrossRef

54.

Bulla R, Bossi F, Agostinis C, Radillo O, Colombo F, De Seta F, et al. Complement production by trophoblast cells at the feto-maternal interface. J Reprod Immunol. 2009;82(2):119–25. https://doi.org/10.1016/j.jri.2009.06.124.PubMedCrossRef

55.

• Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011;58(4):716–24. https://doi.org/10.1161/HYPERTENSIONAHA.111.175919. An important animal model demonstrating that complement C1q is essential for normal placental development independent of activation of the complement pathways. PubMedCrossRef

56.

Agostinis C, Tedesco F, Bulla R. Alternative functions of the complement protein C1q at embryo implantation site. J Reprod Immunol. 2017;119:74–80. https://doi.org/10.1016/j.jri.2016.09.001.PubMedCrossRef

57.

Lokki AI, Heikkinen-Eloranta J, Jarva H, Saisto T, Lokki ML, Laivuori H, et al. Complement activation and regulation in preeclamptic placenta. Front Immunol. 2014;5:312. https://doi.org/10.3389/fimmu.2014.00312.PubMedPubMedCentralCrossRef

58.

Than NG, Romero R, Erez O, Kusanovic JP, Tarca AL, Edwin SS, et al. A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia. Am J Reprod Immunol. 2008;60(4):333–45. https://doi.org/10.1111/j.1600-0897.2008.00631.x.PubMedPubMedCentralCrossRef

59.

Agostinis C, Bossi F, Masat E, Radillo O, Tonon M, De Seta F, et al. MBL interferes with endovascular trophoblast invasion in pre-eclampsia. Clin Dev Immunol. 2012;2012:484321. https://doi.org/10.1155/2012/484321.PubMedCrossRef

60.

Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203(9):2165–75. https://doi.org/10.1084/jem.20061022.PubMedPubMedCentralCrossRef

61.

Qing X, Redecha PB, Burmeister MA, Tomlinson S, D'Agati VD, Davisson RL, et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011;79(3):331–9. https://doi.org/10.1038/ki.2010.393.PubMedCrossRef

62.

Petitbarat M, Durigutto P, Macor P, Bulla R, Palmioli A, Bernardi A, et al. Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating. J Immunol. 2015;195(12):5602–7. https://doi.org/10.4049/jimmunol.1501361.PubMedCrossRef

63.

James JL, Chamley LW, Clark AR. Feeding your baby in utero: how the Uteroplacental circulation impacts pregnancy. Physiology (Bethesda). 2017;32(3):234–45. https://doi.org/10.1152/physiol.00033.2016.

64.

Gillis EE, Williams JM, Garrett MR, Mooney JN, Sasser JM. The Dahl salt-sensitive rat is a spontaneous model of superimposed preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2015;309(1):R62–70. https://doi.org/10.1152/ajpregu.00377.2014.PubMedPubMedCentralCrossRef

65.

Takushima S, Nishi Y, Nonoshita A, Mifune H, Hirata R, Tanaka E, et al. Changes in the nitric oxide-soluble guanylate cyclase system and natriuretic peptide receptor system in placentas of pregnant Dahl salt-sensitive rats. J Obstet Gynaecol Res. 2015;41(4):540–50. https://doi.org/10.1111/jog.12602.PubMedCrossRef

66.

Mattson DL. Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am J Physiol Renal Physiol. 2014;307(5):F499–508. https://doi.org/10.1152/ajprenal.00258.2014.PubMedPubMedCentralCrossRef

67.

Johnson ACGM, Sasser JM. Gene expression changes in uteroplacental development associated with superimposed preeclampsia in the Dahl salt-sensitive rat model. FASEB J Off Publ Fed Am Soc Exp Biol. 2017;31(1):1033.

68.

Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17(4):239–45. https://doi.org/10.1080/14767050500072722.PubMedPubMedCentralCrossRef

69.

Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010;47(7–8):1500–6. https://doi.org/10.1016/j.molimm.2010.01.021.PubMedCrossRef

70.

Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of c5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62(6):1040–5. https://doi.org/10.1161/HYPERTENSIONAHA.113.01420.PubMedCrossRef

71.

• Codsi E, Garovic VD, Gonzalez-Suarez ML, Milic N, Borowski KS, Rose CH, et al. Longitudinal characterization of renal proximal tubular markers in normotensive and preeclamptic pregnancies. Am J Physiol Regul Integr Comp Physiol. 2017;312(5):R773–R8. https://doi.org/10.1152/ajpregu.00509.2016. Confirms the presence of terminal complement activation, as measured by urinary C5b-9, in mild forms of preeclampsia. PubMedCrossRef

72.

Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125(21):3253–62. https://doi.org/10.1182/blood-2014-09-600411.PubMedPubMedCentralCrossRef

73.

•• Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34(2):201–3. https://doi.org/10.1016/j.placenta.2012.11.014. The first demonstration that targeting a complement component resulted in clinical improvement in preeclampsia. PubMedCrossRef

74.

Burwick RM, Burwick NR, Feinberg BB. Eculizumab fails to inhibit generation of C5a in vivo. Blood. 2014;124(23):3502–3. https://doi.org/10.1182/blood-2014-07-589366.PubMedCrossRef

75.

•• Vaught AJ, Gavriilaki E, Hueppchen N, Blakemore K, Yuan X, Seifert SM, et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol. 2016;44(5):390–8. https://doi.org/10.1016/j.exphem.2016.01.005. Demonstrates that the degree of complement activation in serum is similar in severe preeclampsia, HELLP syndrome, and atypical hemolytic uremic syndrome. Describes a potential screening mechanism to identify patients that might benefit from therapies that target the complement system. PubMedPubMedCentralCrossRef

76.

Baines AC, Brodsky RA. Complementopathies. Blood Rev. 2017;31(4):213–23. https://doi.org/10.1016/j.blre.2017.02.003.PubMedCrossRef

77.

• Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–9. https://doi.org/10.1056/NEJMoa1502950. Evidence for safety of C5 blockade in pregnancy. PubMedCrossRef

78.

Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, et al. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Exp Hematol Oncol. 2017;6:4. https://doi.org/10.1186/s40164-017-0064-7.PubMedPubMedCentralCrossRef

79.

Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol CJASN. 2017;12(8):1237–47. https://doi.org/10.2215/CJN.00280117.PubMedCrossRef

80.

Demir E, Yazici H, Ozluk Y, Kilicaslan I, Turkmen A. Pregnant woman with atypical hemolytic uremic syndrome delivered a healthy newborn under eculizumab treatment. Case Rep Nephrol Dial. 2016;6(3):143–8. https://doi.org/10.1159/000454946.PubMedPubMedCentralCrossRef

81.

Hallstensen RF, Bergseth G, Foss S, Jaeger S, Gedde-Dahl T, Holt J, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220(4):452–9. https://doi.org/10.1016/j.imbio.2014.11.003.PubMedCrossRef

82.

Burwick RM, Burwick N, Feinberg BB. Response: Maternal and cord C5a in response to eculizumab. Blood. 2015;126(2):279–80. https://doi.org/10.1182/blood-2015-06-642553.PubMedCrossRef

83.

Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, et al. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clin Immunol. 2017;180:25–32. https://doi.org/10.1016/j.clim.2017.03.012.PubMedCrossRef

84.

Abrahams VM, Chamley LW, Salmon JE. Antiphospholipid syndrome and pregnancy: pathogenesis to translation. Arthritis Rheumatol. 2017; https://doi.org/10.1002/art.40136.

85.

Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol. 1997;110(1):45–52.PubMedPubMedCentralCrossRef

86.

Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol. 1994;152(11):5477–84.PubMed

87.

Regal JF, Strehlke ME, Peterson JM, Wing CR, Parker JE, Nieto NF, et al. Role of IgM and angiotensin II type I receptor autoantibodies in local complement activation in placental ischemia-induced hypertension in the rat. Mol Immunol. 2016;78:38–47. https://doi.org/10.1016/j.molimm.2016.08.016.PubMedPubMedCentralCrossRef

88.

• Lillegard KE, Johnson AC, Lojovich SJ, Bauer AJ, Marsh HC, Gilbert JS, et al. Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol. 2013;56(1–2):91–7. https://doi.org/10.1016/j.molimm.2013.04.009. First demonstration linking complement activation with hypertension following placental ischemia. PubMedPubMedCentralCrossRef

89.

Lillegard KE, Loeks-Johnson AC, Opacich JW, Peterson JM, Bauer AJ, Elmquist BJ, et al. Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats. J Pharmacol Exp Ther. 2014;351(2):344–51. https://doi.org/10.1124/jpet.114.218123.

90.

Wang W, Irani RA, Zhang Y, Ramin SM, Blackwell SC, Tao L, et al. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension. 2012;60(3):712–21. https://doi.org/10.1161/HYPERTENSIONAHA.112.191817.PubMedPubMedCentralCrossRef

91.

Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol. 2004;142(4):756–64. https://doi.org/10.1038/sj.bjp.0705819.PubMedPubMedCentralCrossRef

92.

Regal JF, Lillegard KE, Bauer AJ, Elmquist BJ, Loeks-Johnson AC, Gilbert JS. Neutrophil depletion attenuates placental ischemia-induced hypertension in the rat. PLoS One. 2015;10(7):e0132063. https://doi.org/10.1371/journal.pone.0132063.PubMedPubMedCentralCrossRef

93.

LaMarca B, Wallace K, Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol. 2011;11(2):175–9. https://doi.org/10.1016/j.coph.2011.01.003.PubMedPubMedCentralCrossRef

94.

Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol. 2015;67(1):56–70. https://doi.org/10.1016/j.molimm.2015.02.030.PubMedPubMedCentralCrossRef

95.

Regal JF, Wing CR, McCutcheon L, Gilbert JS, Fleming SD. Endothelin modulates local complement activation in placental ischemia-induced hypertension. Hypertension. 2017;xx(In press).

96.

Intapad S, Warrington JP, Spradley FT, Palei AC, Drummond HA, Ryan MJ, et al. Reduced uterine perfusion pressure induces hypertension in the pregnant mouse. Am J Physiol Regul Integr Comp Physiol. 2014;307(11):R1353–7. https://doi.org/10.1152/ajpregu.00268.2014.PubMedPubMedCentralCrossRef

97.

Fushima T, Sekimoto A, Minato T, Ito T, Oe Y, Kisu K, et al. Reduced uterine perfusion pressure (RUPP) model of preeclampsia in mice. PLoS One. 2016;11(5):e0155426. https://doi.org/10.1371/journal.pone.0155426.PubMedPubMedCentralCrossRef

98.

Soares MJ, Chakraborty D, Karim Rumi MA, Konno T, Renaud SJ. Rat placentation: an experimental model for investigating the hemochorial maternal-fetal interface. Placenta. 2012;33(4):233–43. https://doi.org/10.1016/j.placenta.2011.11.026.PubMedPubMedCentralCrossRef

Titel: The Complement System and Preeclampsia
verfasst von: Jean F. Regal
Richard M. Burwick
Sherry D. Fleming
Publikationsdatum: 01.11.2017
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 11/2017
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-017-0784-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Managing Hypertension in Patients Aged 75 Years and Older

Aortic Stiffness in Aging and Hypertension: Prevention and Treatment with Habitual Aerobic Exercise

Elucidating the Pathogenesis of Pre-eclampsia Using In Vitro Models of Spiral Uterine Artery Remodelling

Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Blood Pressure Parameters and their Associations with Death in Patients with Chronic Kidney Disease